<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Breast Cancer Genomics | Cristea Lab</title>
    <link rel="stylesheet" href="../styles-warm-accent.css">
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <style>
        .research-page {
            margin-top: 100px;
            padding: 3rem 0;
        }
        .research-hero {
            background: linear-gradient(135deg, var(--color-accent), var(--color-accent-hover));
            color: white;
            padding: 4rem 0;
            text-align: center;
            margin-bottom: 4rem;
        }
        .research-hero h1 {
            font-size: 2.5rem;
            margin-bottom: 1rem;
            font-weight: 700;
        }
        .research-hero p {
            font-size: 1.2rem;
            max-width: 800px;
            margin: 0 auto;
            opacity: 0.95;
        }
        .research-section {
            margin-bottom: 4rem;
        }
        .research-section h2 {
            font-size: 2rem;
            color: var(--color-text-primary);
            margin-bottom: 2rem;
            padding-bottom: 0.5rem;
            border-bottom: 2px solid var(--color-accent);
        }
        .project-card {
            background: var(--color-surface-elevated);
            border-radius: var(--radius-xl);
            box-shadow: var(--shadow-sm);
            padding: 2rem;
            margin-bottom: 2rem;
            border: 1px solid var(--color-border);
            transition: var(--transition-normal);
        }
        .project-card:hover {
            box-shadow: var(--shadow-md);
            transform: translateY(-2px);
        }
        .project-card h3 {
            font-size: 1.4rem;
            color: var(--color-text-primary);
            margin-bottom: 1rem;
            font-weight: 600;
        }
        .project-description {
            color: var(--color-text-secondary);
            line-height: 1.7;
            margin-bottom: 1.5rem;
        }
        .key-results {
            background: var(--color-accent-light);
            padding: 1.5rem;
            border-radius: var(--radius-lg);
            margin: 1.5rem 0;
            border-left: 4px solid var(--color-accent);
        }
        .key-results h4 {
            color: var(--color-accent-hover);
            margin-bottom: 0.75rem;
            font-weight: 600;
        }
        .key-results ul {
            list-style-type: none;
            padding: 0;
        }
        .key-results li {
            padding: 0.5rem 0;
            position: relative;
            padding-left: 1.5rem;
        }
        .key-results li::before {
            content: '→';
            position: absolute;
            left: 0;
            color: var(--color-accent);
            font-weight: bold;
        }
        .methodology-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 1.5rem;
            margin: 1.5rem 0;
        }
        .methodology-item {
            background: var(--color-surface);
            padding: 1.5rem;
            border-radius: var(--radius-lg);
            border: 1px solid var(--color-border);
        }
        .methodology-item h5 {
            color: var(--color-text-primary);
            margin-bottom: 0.5rem;
            font-weight: 600;
        }
        .tech-stack {
            display: flex;
            flex-wrap: wrap;
            gap: 0.5rem;
            margin: 1rem 0;
        }
        .tech-tag {
            background: var(--color-accent);
            color: white;
            padding: 0.3rem 0.8rem;
            border-radius: 15px;
            font-size: 0.85rem;
            font-weight: 500;
        }
        .publication-link {
            display: inline-flex;
            align-items: center;
            gap: 0.5rem;
            color: var(--color-accent);
            text-decoration: none;
            font-weight: 500;
            transition: var(--transition-normal);
            margin-right: 1rem;
        }
        .publication-link:hover {
            color: var(--color-accent-hover);
        }
        .impact-box {
            background: linear-gradient(135deg, var(--color-surface), var(--color-surface-elevated));
            padding: 2rem;
            border-radius: var(--radius-xl);
            border: 1px solid var(--color-border);
            margin: 2rem 0;
        }
        .collaboration-info {
            background: var(--color-surface);
            padding: 1rem;
            border-radius: var(--radius-lg);
            margin: 1rem 0;
            border-left: 3px solid var(--color-accent-medium);
        }
        .collaboration-info p {
            margin: 0;
            font-size: 0.95rem;
            color: var(--color-text-secondary);
        }
        .prevention-highlight {
            background: #fef5f5;
            padding: 1.5rem;
            border-radius: var(--radius-lg);
            border-left: 4px solid var(--color-accent);
            margin: 1.5rem 0;
        }
        .prevention-highlight h4 {
            color: var(--color-accent-hover);
            margin-bottom: 0.75rem;
            font-weight: 600;
        }
        @media (max-width: 768px) {
            .research-hero h1 {
                font-size: 2rem;
            }
            .methodology-grid {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="nav-container">
            <div class="nav-brand">
                <h1>Cristea Lab</h1>
                <span class="nav-subtitle">AI Cancer Genomics Research</span>
            </div>
            <ul class="nav-menu">
                <li><a href="../index.html" class="nav-link">Home</a></li>
                <li><a href="../index.html#research" class="nav-link">Research</a></li>
                <li><a href="../index.html#team" class="nav-link">Team</a></li>
                <li><a href="../publications.html" class="nav-link">Publications</a></li>
                <li><a href="../index.html#software" class="nav-link">Software</a></li>
                <li><a href="../index.html#contact" class="nav-link">Contact</a></li>
            </ul>
            <div class="nav-toggle">
                <span class="bar"></span>
                <span class="bar"></span>
                <span class="bar"></span>
            </div>
        </div>
    </nav>

    <!-- Research Page Content -->
    <div class="research-page">
        <!-- Hero Section -->
        <div class="research-hero">
            <div class="container">
                <h1>Breast Cancer Genomics</h1>
                <p>
                    Single-cell analysis of tumor initiation, immune escape mechanisms, and 
                    clinical response prediction with applications to prevention and precision therapy
                </p>
            </div>
        </div>

        <div class="container">
            <!-- Overview -->
            <div class="research-section">
                <h2>Research Overview</h2>
                <div class="project-description">
                    <p>
                        Our breast cancer research program focuses on understanding the earliest events in cancer development, 
                        from stem cell transformations to immune escape during the transition from pre-invasive to invasive disease. 
                        We employ single-cell genomics, spatial analysis, and clinical trial integration to identify novel prevention 
                        strategies and predict treatment responses, with the ultimate goal of preventing cancer before it becomes 
                        clinically apparent.
                    </p>
                </div>
                
                <div class="impact-box">
                    <h4 style="color: var(--color-accent); margin-bottom: 1rem;">Paradigm Shift</h4>
                    <p>
                        Our research represents a fundamental shift from treating established cancers to understanding and preventing 
                        their formation. By identifying protective stem cell populations and developing mRNA vaccine targets, we aim 
                        to transform breast cancer prevention, particularly for high-risk individuals with BRCA mutations or strong 
                        family histories.
                    </p>
                </div>
            </div>

            <!-- Part 1: Tumor Initiation -->
            <div class="research-section">
                <h2>Tumor Initiation & Stem Cell Biology</h2>
                
                <!-- Project A: Novel Stem Cell Population -->
                <div class="project-card">
                    <h3>Novel Stem Cell Population for Breast Cancer Prevention</h3>
                    <div class="project-description">
                        <p>
                            We discovered a novel stem cell population responsible for breast cancer prevention in rat models. 
                            This breakthrough finding challenges conventional understanding of cancer initiation and opens new 
                            avenues for prevention-based therapies, including mRNA vaccine development.
                        </p>
                    </div>

                    <div class="key-results">
                        <h4>Key Discovery</h4>
                        <ul>
                            <li>TGFβ inhibition triggers long-term depletion of cancer progenitor cells</li>
                            <li>Age-dependent decrease in tumor incidence post-treatment</li>
                            <li>Effective prevention of postmenopausal ER+ breast cancer</li>
                            <li>Potential for short-term preventive interventions</li>
                        </ul>
                    </div>

                    <div class="methodology-grid">
                        <div class="methodology-item">
                            <h5>Experimental Model</h5>
                            <p>NMU carcinogen-exposed rat models with TGFβ pathway inhibition</p>
                        </div>
                        <div class="methodology-item">
                            <h5>Analysis Methods</h5>
                            <p>scRNA-seq, FACS purification, connectome analysis</p>
                        </div>
                        <div class="methodology-item">
                            <h5>Clinical Relevance</h5>
                            <p>Pregnancy-induced protection mechanisms</p>
                        </div>
                    </div>

                    <p style="margin-top: 1rem; font-style: italic;">
                        Alečković M*, <strong>Cristea S</strong>* et al. "Breast cancer prevention by short-term inhibition of TGFβ signaling" 
                        <em>Nature Communications</em> 13, 7558, 2022 (*co-first author)
                    </p>

                    <div class="tech-stack">
                        <span class="tech-tag">Stem Cell Biology</span>
                        <span class="tech-tag">Cancer Prevention</span>
                        <span class="tech-tag">TGFβ Signaling</span>
                        <span class="tech-tag">scRNA-seq</span>
                    </div>
                </div>

                <!-- Project B: Secretory Basal Cells -->
                <div class="project-card">
                    <h3>Secretory Basal Cells as Prevention-Associated Progenitors</h3>
                    <div class="project-description">
                        <p>
                            We identified and characterized secretory basal cells (SBCs) as progenitors associated with breast 
                            tumor prevention. These cells serve as potential therapeutic targets for developing mRNA vaccines 
                            and other prevention strategies.
                        </p>
                    </div>

                    <div class="key-results">
                        <h4>Research Highlights</h4>
                        <ul>
                            <li>SBCs identified across multiple mammalian species including humans</li>
                            <li>Main source of insulin-IGF signaling in mammary epithelium</li>
                            <li>Gene signatures predict reduced survival in ER+ breast cancer</li>
                            <li>Deep learning models for cell annotation and characterization</li>
                        </ul>
                    </div>

                    <div class="prevention-highlight">
                        <h4>mRNA Vaccine Development</h4>
                        <p>
                            Our characterization of SBCs provides specific molecular targets for developing preventive 
                            mRNA vaccines that could enhance protective mechanisms in high-risk individuals.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Secretory Basal Cells</span>
                        <span class="tech-tag">mRNA Vaccines</span>
                        <span class="tech-tag">Deep Learning</span>
                        <span class="tech-tag">Cross-species Analysis</span>
                    </div>
                </div>
            </div>

            <!-- Part 2: Immune Analyses -->
            <div class="research-section">
                <h2>Immune Escape & TCR Repertoire Analysis</h2>
                
                <!-- Project A: TCR Clonotype Diversity -->
                <div class="project-card">
                    <h3>Peripheral Blood TCR Diversity as Biomarker</h3>
                    <div class="project-description">
                        <p>
                            We analyzed peripheral blood T-cell receptor (TCR) clonotype diversity in 485 breast cancer patients, 
                            revealing age-associated patterns that predict cancer progression and recurrence. This work enables 
                            non-invasive monitoring through liquid biopsy approaches.
                        </p>
                    </div>

                    <div class="key-results">
                        <h4>Clinical Findings</h4>
                        <ul>
                            <li>Lower TCR diversity in older patients regardless of stage</li>
                            <li>TCR-α diversity predicts de novo stage IV disease in younger patients</li>
                            <li>Higher diversity associated with recurrence in older DCIS patients</li>
                            <li>Distinct blood transcriptome profiles based on TCR diversity</li>
                        </ul>
                    </div>

                    <p style="margin-top: 1rem; font-style: italic;">
                        Nishida J*, <strong>Cristea S</strong>*+ et al. "Peripheral blood TCR clonotype diversity as an age-associated 
                        marker of breast cancer progression" <em>PNAS</em> 120(49), 2023 (*co-first, +co-senior author)
                    </p>

                    <div class="tech-stack">
                        <span class="tech-tag">TCR Sequencing</span>
                        <span class="tech-tag">Liquid Biopsy</span>
                        <span class="tech-tag">Age-Associated Markers</span>
                        <span class="tech-tag">Clinical Biomarkers</span>
                    </div>
                </div>

                <!-- Project B: Cycling T Regulatory Cells -->
                <div class="project-card">
                    <h3>Cycling T Regulatory Cells Drive Immune Escape</h3>
                    <div class="project-description">
                        <p>
                            We discovered a novel cycling T regulatory cell population (cycTreg) that orchestrates the 
                            immunosuppressive environment during the transition from ductal carcinoma in situ (DCIS) to 
                            invasive breast cancer, providing new targets for immunotherapy.
                        </p>
                    </div>

                    <div class="collaboration-info">
                        <p><strong>Status:</strong> Under review at Nature Immunology (co-senior author)</p>
                    </div>

                    <div class="key-results">
                        <h4>Major Discoveries</h4>
                        <ul>
                            <li>cycTregs identified as primary orchestrators of immune escape</li>
                            <li>OX40 agonist + anti-PD-L1 enhances CD8+ T cell infiltration</li>
                            <li>CAF-Treg cross-talk critical for cycTreg expansion</li>
                            <li>cycTregs predict recurrence in grade 1 DCIS</li>
                        </ul>
                    </div>

                    <div class="methodology-grid">
                        <div class="methodology-item">
                            <h5>Patient Samples</h5>
                            <p>DCIS and invasive breast cancer with spatial topology</p>
                        </div>
                        <div class="methodology-item">
                            <h5>Model Systems</h5>
                            <p>Rat tumors recapitulating human breast cancer</p>
                        </div>
                        <div class="methodology-item">
                            <h5>Therapeutic Testing</h5>
                            <p>OX40 agonist and checkpoint inhibitor combinations</p>
                        </div>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Regulatory T cells</span>
                        <span class="tech-tag">Immune Escape</span>
                        <span class="tech-tag">DCIS Progression</span>
                        <span class="tech-tag">Immunotherapy Targets</span>
                    </div>
                </div>
            </div>

            <!-- Part 3: Clinical Applications -->
            <div class="research-section">
                <h2>Clinical Trial Integration & ADC Response</h2>
                
                <!-- Project A: Biopsy Collection Framework -->
                <div class="project-card">
                    <h3>Clinical Trial Biopsy Collection Framework</h3>
                    <div class="project-description">
                        <p>
                            We established a systematic framework for collecting fresh tissues during diagnostic breast biopsies, 
                            enabling real-time single-cell analysis in clinical trials. This infrastructure supports translational 
                            research while maintaining clinical workflow efficiency.
                        </p>
                    </div>

                    <div class="key-results">
                        <h4>Implementation Success</h4>
                        <ul>
                            <li>68.4% consent rate (270/395 patients)</li>
                            <li>446 research specimens collected safely</li>
                            <li>High diagnostic concordance with clinical biopsies</li>
                            <li>Successful single-cell transcriptomic analyses</li>
                        </ul>
                    </div>

                    <p style="margin-top: 1rem; font-style: italic;">
                        Koh SB et al. "Systematic tissue collection during clinical breast biopsy is feasible, safe and 
                        enables high-content translational analyses" <em>npj Precision Oncology</em> 5:85, 2021
                    </p>

                    <div class="tech-stack">
                        <span class="tech-tag">Clinical Trials</span>
                        <span class="tech-tag">Biopsy Protocols</span>
                        <span class="tech-tag">Single-cell Analysis</span>
                        <span class="tech-tag">Translational Research</span>
                    </div>
                </div>

                <!-- Project B: Sacituzumab Govitecan Response -->
                <div class="project-card">
                    <h3>Predicting ADC Response in Triple-Negative Breast Cancer</h3>
                    <div class="project-description">
                        <p>
                            We conducted spatio-temporal profiling of Sacituzumab Govitecan response in the NeoSTAR trial, 
                            analyzing 50 patients with localized TNBC. Our integrated analysis reveals predictors of pathologic 
                            complete response beyond TROP2 expression levels.
                        </p>
                    </div>

                    <div class="key-results">
                        <h4>Response Predictors</h4>
                        <ul>
                            <li>Chronic interferon signatures associated with residual disease</li>
                            <li>CXCL13+ exhausted CD8+ T cells enriched in complete responders</li>
                            <li>Suppressive M2 macrophage interactions predict resistance</li>
                            <li>Quiescent tumor cells in immune-poor neighborhoods resist therapy</li>
                        </ul>
                    </div>

                    <div class="methodology-grid">
                        <div class="methodology-item">
                            <h5>Trial Design</h5>
                            <p>Pre/post treatment biopsies from NeoSTAR trial</p>
                        </div>
                        <div class="methodology-item">
                            <h5>Analysis Methods</h5>
                            <p>scRNA-seq, 16-plex Orion imaging, exome sequencing</p>
                        </div>
                        <div class="methodology-item">
                            <h5>Clinical Impact</h5>
                            <p>Biomarkers for patient selection and combination strategies</p>
                        </div>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Antibody-Drug Conjugates</span>
                        <span class="tech-tag">Sacituzumab Govitecan</span>
                        <span class="tech-tag">TNBC</span>
                        <span class="tech-tag">Spatial Profiling</span>
                        <span class="tech-tag">Clinical Biomarkers</span>
                    </div>
                </div>
            </div>

            <!-- Publications -->
            <div class="research-section">
                <h2>Selected Publications</h2>
                <div class="project-card">
                    <div class="project-description">
                        <p><strong>Alečković M*</strong>, <strong>Cristea S*</strong> et al. 
                        "Breast cancer prevention by short-term inhibition of TGFβ signaling" 
                        <em>Nature Communications</em> 13, 7558, 2022.</p>
                        
                        <p style="margin-top: 1rem;"><strong>Nishida J*</strong>, <strong>Cristea S*+</strong> et al. 
                        "Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression" 
                        <em>PNAS</em> 120(49), 2023.</p>
                        
                        <p style="margin-top: 1rem;"><strong>Bui T</strong> et al., <strong>Cristea S+</strong>, Polyak K+. 
                        "Cycling T Regulatory Cells Architect an Immune Escape Hub During In Situ to Invasive Breast Carcinoma Transition" 
                        <em>Under review at Nature Immunology</em>, 2025.</p>
                    </div>
                </div>
            </div>

            <!-- Future Directions -->
            <div class="research-section">
                <h2>Future Directions</h2>
                <div class="impact-box">
                    <p>
                        While our breast cancer research continues with established collaborators at Dana-Farber and Harvard, 
                        we are translating our methodological innovations to pancreatic cancer research. The single-cell 
                        analysis frameworks, spatial profiling techniques, and immune modeling approaches developed for 
                        breast cancer provide a strong foundation for advancing pancreatic cancer early detection and 
                        treatment strategies at the Hale Center.
                    </p>
                </div>
            </div>

            <!-- Back Navigation -->
            <div class="text-center" style="margin-top: 3rem;">
                <a href="../index.html#research" class="btn btn-secondary">Back to Research Overview</a>
            </div>
        </div>
    </div>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <div class="footer-content">
                <div class="footer-logo">
                    <h3>Cristea Lab</h3>
                    <p>AI Cancer Genomics Research</p>
                </div>
                <div class="footer-links">
                    <a href="https://www.dana-farber.org" target="_blank">Dana-Farber Cancer Institute</a>
                    <a href="https://www.harvard.edu" target="_blank">Harvard University</a>
                </div>
                <div class="footer-social">
                    <a href="#" class="social-link"><i class="fab fa-twitter"></i></a>
                    <a href="#" class="social-link"><i class="fab fa-github"></i></a>
                    <a href="#" class="social-link"><i class="fab fa-linkedin"></i></a>
                </div>
            </div>
            <div class="footer-bottom">
                <p>&copy; 2025 Cristea Lab. All rights reserved.</p>
            </div>
        </div>
    </footer>

    <script src="../script-clean-modern.js"></script>
</body>
</html>